Skip to main content

The nuclear medicine department of the Institut Jules Bordet offers patients diagnostic tests of the functional or molecular type, as well as treatments with targeted molecular radiotherapy.  

The diagnostic tests differ from those carried out in the Radiology Department in that they involve the intravenous administration of substances labelled with radioactive isotopes, which specifically make it possible to identify the functionality or characteristic of an organ or of the cancer.

Therapeutic applications in nuclear medicine (often called “molecular radiotherapy”) use the same type of substance (tracer) specifically targeting the cancer tissue, but this substance is labelled with radioactive isotopes which emit therapeutic particles of the beta or alpha type enabling the destruction of the diseased cells.

Research projects

Project 1

Somatostatin receptors imaging in relapsing and refractory multiple myeloma patients.

Project 2

MOLECULAR BIOMARKERS IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER: PSMA EXPRESSION, METABOLIC ACTIVITY, AND CIRCULATING CELL-FREE DNA.

Project 3

Molecular imaging of the tumor microenvironment

Project 4

Lutetium-177 dosimetry as a predictive biomarker of response in metastatic castrate resistant prostate cancer patients treated with psma radioligand therapy. the ludopath trial

Project 5

USE OF ARTIFICIAL INTELLIGENCE IN NUCLEAR MEDECINE

Project 6

Etude pilote d’imagerie PSMA-PET/CT en vue d’explorer la possibilité d’une thérapie basée sur le PSMA comme future option thérapeutique chez les patientes atteintes d’un cancer du sein métastatique triple négatif.

Project 7

Evaluation préopératoire de la carcinomatose péritonéale par la moyen d’un FAPI-PET/CT.

Our team

Head of Department
- Prof Patrick Flamen

The team
- Dr Géraldine Gebhart, H
ead of Clinic
- Dr Carlos ArtigasAssistant Head of Clinic
Dr Ioannis KarfisAssistant Head of Clinic
- Dr Elçin ÖzalpAssistant Head of Clinic
- Dr Erwin WoffAssistant Head of Clinic
- Dr Anne-Leen Deleu, Resident
- Dr Isabel Marin Melero, Resident

Radiophysicists (Department of Radiophysics)
Bruno Vanderlinden, Radiophysicist
Clémentine Marin, Radiophysicist 
Gwennaëlle MarinRadiophysicist

Physics control
Marie Christiane Yimo-Wadje
Théo Moschidis

Radiopharmacy
- Prof. 
Zéna WimanaManager Radiopharmacy
- Prof. Ghanem Ghanem
- Adriana De Matos, Operator Radiopharmacy
- Kadidja Ouldadda, Operator Radiopharmacy
Sigrid Vercauteren, Radiopharmacist

Coordination of radionuclide treatments
- Marie-Noëlle Gheeraert
- Pauwel Thijs

Research Unit
- Prof. Zéna Wimana, Radiopharmacy/pre-clinical imaging
- Wendy Delbart, PhD Student/Research Assistant/ Biomedical Sciences, ULB
Loubna Taraji Schiltz, Clinical Study Coordinator
- Magdalena Mileva, MD, PhD Student/ Biomedical Sciences, ULB

- Qaid Shagera, MD, PhD Student/ Biomedical Sciences, ULB
- Ester Vicastillo Paredes, PhD Student/ Biomedical Sciences, ULB
- Gabriela Critchi,
Research Assistant

Technologists
- Sara Coelho, Head of Technologists

Secretaries
- Jessie Toussaint
- Anandi Henriet
- Alyssa Hammouda (PET-scan/Isotopes)
- Naïma Chadya (PET-scan/Isotopes)

16/12/2022

 Scientific publications

[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.

Authors : Iqbal R, Yaqub M, Bektas HO, Oprea-Lager DE, de Vries EGE, Glaudemans AWJM, Aftimos P, Gebhart G, Beelen AP, Schuit RC, Windhorst AD, Boellaard R, Menke-van der Houven van Oordt CW
Year : 2023
Journal : Clin Cancer Res

Lymphatic Alterations Under Tattoos: Preliminary Reports of One Observational Study.

Authors : Bourgeois P, Roman MM, Schweicher J, Lavoisier P, Maquet P, Karler C, Lizewski M, Fouarge A, Cuylits N, Del Marmol V, Leduc O
Year : 2023
Journal : Clin Cosmet Investig Dermatol
Volume : 16
Pages : 257-265

PIK3CA copy number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer.

Authors : Amato O, Buisseret L, Gebhart G, Plouznikoff N, Larsimont D, Awada A, Piccart M, Aftimos P
Year : 2023
Journal : Cold Spring Harb Mol Case Stud

(68)Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy.

Authors : Shagera QA, Artigas C, Karfis I, Critchi G, Chanza NM, Sideris S, Peltier A, Paesmans M, Gil T, Flamen P
Year : 2022
Journal : J Nucl Med
Volume : 63
Pages : 1191-1198

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 38